AQU 005
Alternative Names: AQU-005; NM-AQU-005Latest Information Update: 28 Jul 2019
Price :
$50 *
At a glance
- Originator Aquilus Pharmaceuticals
- Developer NeuroMax
- Class Analgesics; Small molecules
- Mechanism of Action Matrix metalloproteinase 2 inhibitors; Matrix metalloproteinase 9 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in Russia
- 29 Jun 2016 Phase-I clinical trials in Neuropathic pain in Russia (unspecified route)
- 24 Jun 2013 Preclinical trials in Neuropathic pain in Russia (unspecified route)